Principal Investigator
David Crawford
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20220901
Clinical Trial Summary
BTX-AUT-001
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited
Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease and Severe Vaso-Occlusive Crises (BEACON TRIAL)
Phase
Phase I/II
Funding Agency/Sponsor
Industry
Disease
Hematology/Oncology
Contact Information
Study Contact
Grace Alvarez
Phone Number
+1 (305) 2434447
Email
galvarez2@miami.edu